Saudi Maaden to set up USD5.6b phosphate project
22 February 2012, 3:28 am
(MENAFN) Saudi Arabian Mining Co. (Maaden) unveiled plans to spend USD5.6 billion on a phosphate project in Umm Wual, north of the Saudi Arabia, expected to run buy the end of 2016, Reuters ...

Press Release
21 February 2012, 10:08 am
AstraZeneca (NYSE: AZN) announced today that the American College of Chest Physicians (ACCP) has updated its guidelines on Antithrombotic Therapy and Prevention of Thrombosis to include a recommendation for giving the oral antiplatelet medicine, BRILINTA® (ticagrelor) tablets with low-dose aspirin to patients who suffer from Acute Coronary Syndrome (ACS).

BRILINTA® (ticagrelor) Added to American College of Chest Physicians Recommendations on Antithrombotic Therapy and ...
21 February 2012, 9:00 am
AstraZeneca announced today that the American College of Chest Physicians has updated its guidelines on Antithrombotic Therapy and Prevention of Thrombosis to in

Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell ...
6 February 2012, 7:30 am
RESEARCH TRIANGLE PARK, N.C., Feb. 6, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase ...

Personalized Medicine - Scientific & Commercial Aspects
1 February 2012, 4:55 am
NEW YORK, Feb. 1, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Personalized Medicine - scientific & commercial aspects http://www.reportlinker.com/p0203549/Personalized-Medicine---scientific--commercial-aspects.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=GenomicsThe ...

Chimerix Announces Presentation of Final Data from CMX001 Phase 2 Trial in Prophylaxis of Cytomegalovirus in ...
25 January 2012, 11:00 am
RESEARCH TRIANGLE PARK, N.C., Jan. 25, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced that final data from CMX001 Study 201, a Phase ...